Skip to main content

Table 1 Ordered logistic regression analysis for radiologic progression at 11 years

From: Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial

Variable at baseline Odds ratio (95% CI) Pvalue
Female sex 1.74 (0.84 to 3.60) 0.13
Age, years 0.99 (0.96 to 1.02) 0.60
Disease duration before diagnosis, months 1.02 (0.94 to 1.10) 0.68
Rheumatoid factor positivity 3.17 (1.45 to 6.92) 0.004
Erythrocyte sedimentation rate 1.01 (0.99 to 1.02) 0.33
Larsen score 0.99 (0.94 to 1.05) 0.77
Initial randomization group   0.016
FIN-RACo 1.00 (reference)  
SINGLE 2.39 (1.78 to 4.84)  
  1. Radiologic progression in hands and feet was determined according to the tertiles of Larsen score changes (categories 0 to 1, 2 to 17, and ≥18). FIN-RACo, study group treated for the first 2 years with a combination of three disease-modifying antirheumatic drugs, initially methotrexate, sulfasalazine, and hydroxychloroquine, with prednisolone; SINGLE, study group treated for the first 2 years with one disease-modifying antirheumatic drug, initially sulfasalazine, with or without prednisolone.